Jakafi XR is Approved by the FDA for Myelofibrosis

The announcement on May 1st, 2026, that Jakafi XR has been approved by the FDA for patients managing myelofibrosis offers a new dosing option. Prior to this announcement, Jakafi (also sold in some countries with brand name Jakavi) was widely used in treatment of this and other conditions,, but had to be prescribed off-label. Now […]

Jakafi is a preferred treatment for myelofibrosis

Myelofibrosis is a type of bone marrow cancer that leads to the formation of fibrous tissue in the bone marrow and results in scarring, which impairs the normal production of blood cells. The exact cause of myelofibrosis is unknown, but it is believed to be caused by genetic mutations in the blood cells. Jakafi (ruxolitinib) […]